论文部分内容阅读
目的探讨长春西汀辅助治疗椎-基底动脉供血不足性眩晕(VBIV)的临床疗效。方法选取2014年3月—2015年3月盐城市第一人民医院收治的VBIV患者112例,根据治疗意愿将其分为对照组和观察组各56例。入院后,两组患者均给予常规对症治疗,同时口服氟桂利嗪胶囊和阿司匹林肠溶片。对照组患者在常规对症治疗的基础上静脉滴注丹参川芎嗪;观察组患者在常规对症治疗基础上静脉滴注长春西汀,14 d为1个疗程。比较两组患者的临床疗效、血液流变学指标及不良反应发生情况。结果观察组患者的临床疗效优于对照组(P<0.05)。治疗前两组患者全血高切黏度、全血低切黏度、血浆黏度及血细胞比容比较,差异无统计学意义(P>0.05);治疗后观察组患者全血高切黏度、全血低切黏度、血浆黏度及血细胞比容均低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论长春西汀辅助治疗VBIV的临床疗效确切,可改善患者的血液流变学指标,且不良反应较少。
Objective To investigate the clinical efficacy of vinpocetine in the treatment of vertebrobasilar insufficiency vertigo (VBIV). Methods One hundred and two patients with VBIV who were treated in Yancheng First People’s Hospital from March 2014 to March 2015 were selected and divided into control group and observation group with 56 cases each. After admission, both groups were given conventional symptomatic treatment, while oral flunarizine capsules and aspirin enteric-coated tablets. Patients in the control group were given intravenous infusion of Ligustrazine on the basis of conventional symptomatic treatment. In the observation group, vinpocetine was intravenously administered on the basis of routine symptomatic treatment, and for 14 days, one course of treatment was given. The clinical efficacy, hemorheological parameters and adverse reactions of the two groups were compared. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in the whole blood viscosity, the whole blood low-cut viscosity, the plasma viscosity and the hematocrit before treatment in the two groups (P> 0.05). After treatment, the observation group had high whole blood viscosity, low whole blood Cut viscosity, plasma viscosity and hematocrit were lower than the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Vinpocetine adjuvant treatment of VBIV clinical curative effect is accurate, can improve the patient’s hemorheological indicators, and fewer adverse reactions.